DV
Dividend Vision

DTCFF — Defence Therapeutics Inc

Defence Therapeutics Inc (DTCFF)

Total return is -86.6% over the past 5.2 years, 188.9 points behind SPY at 102.3%. Its deepest 1-year drawdown was 61.5%.

Defence Therapeutics Inc is an equity stock focused on the biotechnology and therapeutics sector. The fund holds limited publicly available data regarding distribution frequency, yield profile, and expense ratio metrics. This holding appeals primarily to investors interested in exposure to specialized therapeutic development companies rather than traditional dividend income strategies.

DTCFF key facts

Asset type
Stock
Asset class
Equity
Inception date
05/18/2021
Distribution frequency
None
Last close
$0.34
Market cap
$21,576,888
Average volume
8530.0
Beta
1.33
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.07